Nonviral Gold Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Ribonucleoprotein and Long DNA Transgenes Into Primary Blood Cells

Gene editing using CRISPR systems has gained traction for its potential to treat various diseases, but delivery remains a major challenge. We have previously reported an entirely synthetic gold nanoparticle formulation which can safely and effectively deliver multiple different CRISPR systems as ribonucleoprotein (RNP) into hematopoietic stem cells and immune cells. Here, we describe a modified version of this nanoparticle to simultaneously deliver CRISPR Cas9 RNP and transgene-encoding DNA templates (HDT) as long as ~2.1 kb. We evaluate this HDT-CRISPR-AuNP for gene editing at two loci of interest with different transgene cargo. These nanoparticles successfully deliver gene editing into primary human T cells and hematopoietic stem and progenitor cells with insertion of an antigen-specific T cell receptor transgene. This proof-of-concept immune engineering study demonstrates a simple, synthetic nanoformulation for co-delivery of all cargo required for CRISPR-mediated delivery of transgene cassettes with potential for efficacy in vivo.

Authors

Institutions

Publication Details

Journal
Advanced NanoBiomed Research
Published
2026-03-31
DOI
https://doi.org/10.1002/anbr.202500242
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nonviral Gold Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Ribonucleoprotein and Long DNA Transgenes Into Primary Blood Cells

Katrina Poljakov, Jennifer E. Adair, Aude G. Chapuis, Rachel Cunningham et al.
Advanced NanoBiomed Research
CRISPR and Genetic Engineering
article

Nonviral Gold Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Ribonucleoprotein and Long DNA Transgenes Into Primary Blood Cells

Katrina Poljakov, Jennifer E. Adair, Aude G. Chapuis, Rachel Cunningham, Daniel D. Lane, Alessandro Rizzi, Mark Enstrom, Patricia Lipson, Karthikeya S. V. Gottimukkala
article en

Abstract

Gene editing using CRISPR systems has gained traction for its potential to treat various diseases, but delivery remains a major challenge. We have previously reported an entirely synthetic gold nanoparticle formulation which can safely and effectively deliver multiple different CRISPR systems as ribonucleoprotein (RNP) into hematopoietic stem cells and immune cells. Here, we describe a modified version of this nanoparticle to simultaneously deliver CRISPR Cas9 RNP and transgene-encoding DNA templates (HDT) as long as ~2.1 kb. We evaluate this HDT-CRISPR-AuNP for gene editing at two loci of interest with different transgene cargo. These nanoparticles successfully deliver gene editing into primary human T cells and hematopoietic stem and progenitor cells with insertion of an antigen-specific T cell receptor transgene. This proof-of-concept immune engineering study demonstrates a simple, synthetic nanoformulation for co-delivery of all cargo required for CRISPR-mediated delivery of transgene cassettes with potential for efficacy in vivo.

Advanced NanoBiomed Research
University of Massachusetts Chan Medical School (US), University of Washington (US), Fred Hutch Cancer Center (US)
Bill and Melinda Gates Foundation, Fred Hutchinson Cancer Research Center, University of Washington, National Institutes of Health, Office of Research Infrastructure Programs, National Institutes of Health
Openalex Percentile: Top 37%
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.